Add news
March 2010
April 2010
May 2010June 2010July 2010
August 2010
September 2010October 2010
November 2010
December 2010
January 2011
February 2011March 2011April 2011May 2011June 2011July 2011August 2011September 2011October 2011November 2011December 2011January 2012February 2012March 2012April 2012May 2012June 2012July 2012August 2012September 2012October 2012November 2012December 2012January 2013February 2013March 2013April 2013May 2013June 2013July 2013August 2013September 2013October 2013November 2013December 2013January 2014February 2014March 2014April 2014May 2014June 2014July 2014August 2014September 2014October 2014November 2014December 2014January 2015February 2015March 2015April 2015May 2015June 2015July 2015August 2015September 2015October 2015November 2015December 2015January 2016February 2016March 2016April 2016May 2016June 2016July 2016August 2016September 2016October 2016November 2016December 2016January 2017February 2017March 2017April 2017May 2017June 2017July 2017August 2017September 2017October 2017November 2017December 2017January 2018February 2018March 2018April 2018May 2018June 2018July 2018August 2018September 2018October 2018November 2018December 2018January 2019February 2019March 2019April 2019May 2019June 2019July 2019August 2019September 2019October 2019November 2019December 2019January 2020February 2020March 2020April 2020May 2020June 2020July 2020August 2020September 2020October 2020November 2020December 2020
News Every Day |

Chinese coronavirus vaccine appears safe and induces immune response

There are now several promising vaccine candidates
There are now several promising vaccine candidates (Picture: Getty)

A Chinese vaccine candidate for coronavirus is showing promise, according to preliminary study results.

It appears to be safe and induces an immune response in healthy volunteers.

Phase one/two trials of an inactivated SARS-CoV-2 vaccine candidate – CoronaVac – involved more than 700 healthy volunteers aged 18-59 recruited in China between April 16 and May 5.

According to preliminary results published in The Lancet Infectious Diseases, the vaccine appeared to be safe and well tolerated at all tested doses.

Visit our live blog for the latest updates Coronavirus news live

The most common reported side effect was pain at the injection site.

Within 14 days of the final dose, researchers detected robust antibody responses after two jabs of the vaccine candidate were given two weeks apart.

(FILES) This file photo taken on September 24, 2020 shows a staff member working during a media tour of a new factory built to produce a Covid-19 coronavirus vaccine at Sinovac, one of 11 Chinese companies approved to carry out clinical trials of potential coronavirus vaccines, in Beijing. (Photo by WANG Zhao / AFP) / TO GO WITH STORY virus-??pid??mie-sant??-vaccins-Chine by Ludovic Ehret (Photo by WANG ZHAO/AFP via Getty Images)
A staff member working during a media tour of a new factory built to produce a Covid-19 coronavirus vaccine at Sinovac, one of 11 Chinese companies approved to carry out clinical trials of potential coronavirus vaccines, in Beijing (Picture: Getty)

This was even the case for the lowest dose tested, three micrograms.

Researchers say antibody levels induced by the vaccine were lower than those seen in people who had been infected by and recovered from Covid-19.

But they add that the vaccine could provide protection from the virus.

It means there are now several promising vaccine candidates. Pfizer recently announced they had found a vaccine which appeared to be more than 90% effective in early studies. US company Moderna also announced it had found a vaccine which was almost 95% effective.

The primary objective of the study of the Chinese vaccine was to evaluate the immune response and safety of the vaccine, and it was not designed to assess how effective it is at preventing infection with SARS-CoV-2, the virus that causes Covid-19.

Findings from phase three studies will be crucial for determining if the immune response generated by CoronaVac is sufficient to protect from infection.

According to the paper, antibody responses could be induced within 28 days of the first immunisation, by giving two doses of the vaccine candidate 14 days apart.

The study only included healthy adults aged 18 to 59 years and further studies will be needed to test the vaccine candidate in other age groups, as well as in people who have pre-existing medical conditions.

Professor Fengcai Zhu, joint lead author of the study, from the Jiangsu Provincial Centre for Disease Control and Prevention, Nanjing, China, said: ‘Our findings show that CoronaVac is capable of inducing a quick antibody response within four weeks of immunisation by giving two doses of the vaccine at a 14-day interval.

‘We believe that this makes the vaccine suitable for emergency use during the pandemic.

‘In the longer term, when the risk of Covid-19 is lower, our findings suggest that giving two doses with a one-month interval, rather than a two-week interval, might be more appropriate for inducing stronger and potentially longer-lasting immune responses.

‘However, further studies are needed to check how long the antibody response remains after either vaccination schedule.’

CoronaVac is a chemically-inactivated whole-virus vaccine based on a strain of SARS-CoV-2 that was originally isolated from a patient in China.

The authors note several limitations to their study, including that the phase two trial did not assess T cell responses, which are another arm of the immune response to virus infections.

This will be studied in ongoing phase three studies.

Writing in a linked comment, Dr Naor Bar-Zeev, from Johns Hopkins University, who was not involved in the study, said: ‘Like all phase two trials, the results must be interpreted with caution until phase three results are published.

‘But even then, after phase three trial completion and after licensure, we should prudently remain cautious.’

Get in touch with our news team by emailing us at

For more stories like this, check our news page.

Read also

Bus Route Planning to Cost State Fantastic Amount

Liverpool vs Ajax: Live stream FREE, TV channel, team news and kick-off time for TONIGHT’s big Champions League clash

Covid deaths start to slow for first time since second wave hit in September, stats show

News, articles, comments, with a minute-by-minute update, now on — latest news 24/7. You can add your news instantly now — here